Causes of death in patients undergoing percutaneous coronary intervention with drug-eluting stents in a real-world
Michael S Lee1, Timothy Canan, Alice Perlowski
1David Geffen School of Medicine at University of California, Los Angeles, Division of Cardiology, Los Angeles, California, USA. mslee@mednet.ucla.edu
Insights
Drug-eluting stents (DES) show similar rates of cardiac and non-cardiac death. PCI-related death and stent thrombosis were low, with most deaths occurring post-discharge.
Area of Science:
- Cardiology
- Interventional Cardiology
- Public Health
Background:
- Concerns exist regarding the long-term safety of drug-eluting stents (DES).
- Stent thrombosis and patient mortality are key areas of debate.
- This study investigates specific causes of death in patients receiving DES.
Purpose of the Study:
- To determine the causes of death in patients treated with DES.
- To analyze the safety profile of DES in a high-risk patient population.
- To differentiate between cardiac and non-cardiac mortality post-DES implantation.
Main Methods:
- Retrospective analysis of 1,023 patients undergoing percutaneous coronary intervention (PCI) with DES.
- Data collection via medical records, physician contact, and death certificates.
- Follow-up at a mean of 2.9 years to ascertain mortality and causes of death.
Main Results:
- Overall mortality was 9.4% (96/1023) over a mean follow-up of 2.9 years.
- Cardiac (44 deaths) and non-cardiac (43 deaths) causes were similarly represented.
- PCI-related death was 1.3%, including 1.1% from stent thrombosis; 1.4% died from myocardial infarction, and 1.4% from heart failure.
Conclusions:
- Cardiac and non-cardiac deaths contribute equally to mortality in high-risk patients treated with DES.
- PCI-related death and stent thrombosis are infrequent.
- Most deaths occurred after hospital discharge, often in patients with acute myocardial infarction.
Background:
Reports of stent thrombosis and death in patients who have received drug-eluting stents (DES) have provoked debate regarding their long-term safety. We investigated the specific causes of death in patients receiving DES at an academic tertiary-care center.
Methods:
A retrospective analysis of 1,023 consecutive patients who underwent percutaneous coronary intervention (PCI) with DES from 2003 to 2006 at UCLA Medical Center was performed. Dates and cause of death were obtained by reviewing the patient's medical record, contacting the patient's doctor, or accessing the Social Security Death Index and obtaining copies of death certificates at the Los Angeles County Registrar-Recorder/County Clerk office. If the cause of death could not be determined, it was reported "unknown."
Results:
At a mean follow up of 2.9 +/- 1.3 years, 96 patients who underwent PCI with DES died during the analysis (9.4% mortality). The mean duration between index PCI and death was 331 +/- 324 days. The cause of death was unknown in 9 patients, thus the analysis was based upon 87 patients. There were similar number of cardiac (n = 44) and non-cardiac deaths (n = 43). The risk of PCI-related death was 1.3% (13/1023), which included 11 patients (1.1%) who died from stent thrombosis. Fourteen patients (1.4%) who presented with myocardial infarction (MI) and underwent PCI died, and 14 patients (1.4%) died from heart failure. Non-cardiac deaths included cancer, infection, respiratory failure and a cerebrovascular event. Age, chronic renal insufficiency, presentation with MI, chronic obstructive pulmonary disease, history of cerebrovascular event, orthotopic heart transplantation and left ventricular ejection fraction were significantly associated with increased mortality.
Conclusions:
Cardiac and non-cardiac causes of death contributed similarly to mortality in patients who underwent PCI with DES at a large tertiary care center that manages high-risk patients. Overall PCI-related death and stent thrombosis causing death were low. The majority of deaths occurred in patients after hospital discharge. The majority of patients who died in the hospital presented with acute MI and were in critical condition on presentation.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Coronary Artery Disease III: Clinical Manifestations
01:27Coronary Artery Disease V: Interprofessional Care
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...